No profile data available.
Enveric Biosciences, Inc. (ENVB) is a healthcare company in the brain and nerve treatment drugs industry, based in Cambridge, United States, with about 5 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$12.13 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $0. Its market capitalization was $6.49 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications.
Enveric Biosciences reported $0 in revenue for fiscal year 2025. In Q1 2026 revenue was $0.
$6.49 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include NeuroSense Therapeutics Ltd. (NRSN), Brainstorm Cell Therapeutics Inc. (BCLI), Reviva Pharmaceuticals Holdings, Inc. (RVPH), Alzamend Neuro, Inc. (ALZN).